Cutaneous manifestations in mevalonate kinase deficient patients treated with canakinumab

Research output: Contribution to journalArticlepeer-review

Abstract

Canakinumab is a human monoclonal antibody anti-interleukin-1β, it is the only biologic drug approved to treat mevalonate kinase deficiency (MKD). Canakinumab injection can trigger several local cutaneous reactions, but also chronic-relapsing skin infections and other manifestations. We report three cases of unusual cutaneous manifestations in patients treated with canakinumab.

Original languageEnglish
Pages (from-to)760-762
Number of pages3
JournalClinical and Experimental Rheumatology
Volume38
Issue number4
Publication statusPublished - Jul 1 2020

Keywords

  • Canakinumab
  • Mevalonate kinase deficiency

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Cutaneous manifestations in mevalonate kinase deficient patients treated with canakinumab'. Together they form a unique fingerprint.

Cite this